{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:45:40Z","timestamp":1792259140151,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun. Health"],"DOI":"10.1038\/s44528-026-00039-w","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:05:36Z","timestamp":1792224336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of plasma lipids as non-invasive signatures for metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1038","volume":"1","author":[{"given":"Ali","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipankar","family":"Malakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Maan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagnik","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabreena","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Shalimar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishaan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2281-078X","authenticated-orcid":false,"given":"Ujjaini","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"39_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 https:\/\/doi.org\/10.1097\/HEP.0000000000000520 (2023).","journal-title":"Hepatology"},{"key":"39_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3350\/CMH.2022.0365","volume":"29","author":"MLP Teng","year":"2023","unstructured":"Teng, M. L. P. et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29, 32\u201342 https:\/\/doi.org\/10.3350\/CMH.2022.0365 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"39_CR3","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jceh.2022.11.014","volume":"13","author":"SP Duseja","year":"2023","unstructured":"Duseja, S. P. et al. Chawla, Indian national association for study of the liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD). J. Clin. Exp. Hepatol. 13, 273\u2013302 https:\/\/doi.org\/10.1016\/j.jceh.2022.11.014 (2023).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"39_CR4","unstructured":"Girish, V. & John, S. Metabolic Dysfunction-Associated Steatotic Liver Disease (M\u0391SLD) https:\/\/pubmed.ncbi.nlm.nih.gov\/31082077 (StatPearls Publishing, 2025)."},{"key":"39_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jceh.2021.11.010","volume":"12","author":"A Shalimar","year":"2022","unstructured":"Shalimar, A. et al. Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis. J. Clin. Exp. Hepatol. 12, 818\u2013829 https:\/\/doi.org\/10.1016\/j.jceh.2021.11.010 (2022).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"39_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VWS Wong","year":"2018","unstructured":"Wong, V. W. S., Adams, L. A., de L\u00e9dinghen, V., Wong, G. L. H. & Sookoian, S. Noninvasive biomarkers in NAFLD and NASH\u2014current progress and future promise. Nat. Rev. Gastroenterol. Hepatol. 15, 461\u2013478 https:\/\/doi.org\/10.1038\/s41575-018-0014-9 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"39_CR7","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","volume":"155","author":"G Musso","year":"2018","unstructured":"Musso, G., Cassader, M., Paschetta, E. & Gambino, R. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology 155, 282\u2013302.e8 https:\/\/doi.org\/10.1053\/j.gastro.2018.06.031 (2018).","journal-title":"Gastroenterology"},{"key":"39_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100479","volume":"4","author":"B Paul","year":"2022","unstructured":"Paul, B., Lewinska, M. & Andersen, J. B. Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 4, 100479 https:\/\/doi.org\/10.1016\/j.jhepr.2022.100479 (2022).","journal-title":"JHEP Rep."},{"key":"39_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101185","volume":"6","author":"F Carli","year":"2024","unstructured":"Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A. & Gastaldelli, A. Lipid metabolism in MASLD and MASH: From mechanism to the clinic. JHEP Rep. 6, 101185 https:\/\/doi.org\/10.1016\/j.jhepr.2024.101185 (2024).","journal-title":"JHEP Rep."},{"key":"39_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100477","volume":"4","author":"AJ McGlinchey","year":"2022","unstructured":"McGlinchey, A. J. et al. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Rep. 4, 100477 https:\/\/doi.org\/10.1016\/j.jhepr.2022.100477 (2022).","journal-title":"JHEP Rep."},{"key":"39_CR11","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1021\/pr1002593","volume":"9","author":"J Barr","year":"2010","unstructured":"Barr, J. et al. Liquid chromatography\u2212mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J. Proteome Res. 9, 4501\u20134512 https:\/\/doi.org\/10.1021\/pr1002593 (2010).","journal-title":"J. Proteome Res."},{"key":"39_CR12","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jhep.2021.04.013","volume":"75","author":"GJ Ooi","year":"2021","unstructured":"Ooi, G. J. et al. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. J. Hepatol. 75, 524\u2013535 https:\/\/doi.org\/10.1016\/j.jhep.2021.04.013 (2021).","journal-title":"J. Hepatol."},{"key":"39_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2337\/dc17-1318","volume":"41","author":"M Apostolopoulou","year":"2018","unstructured":"Apostolopoulou, M. et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis. Diab. Care 41, 1235\u20131243 https:\/\/doi.org\/10.2337\/dc17-1318 (2018).","journal-title":"Diab. Care"},{"key":"39_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12944-021-01526-5","volume":"20","author":"YN Flores","year":"2021","unstructured":"Flores, Y. N. et al. Serum lipids are associated with nonalcoholic fatty liver disease: a pilot case-individuals study in Mexico. Lipids Health Dis. 20, 136 https:\/\/doi.org\/10.1186\/s12944-021-01526-5 (2021).","journal-title":"Lipids Health Dis."},{"key":"39_CR15","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/hep.21763","volume":"46","author":"P Puri","year":"2007","unstructured":"Puri, P. et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46, 1081\u20131090 https:\/\/doi.org\/10.1002\/hep.21763 (2007).","journal-title":"Hepatology"},{"key":"39_CR16","doi-asserted-by":"publisher","unstructured":"Yang, R. X. et al. Serum monounsaturated triacylglycerol predicts steatohepatitis in patients with non-alcoholic fatty liver disease and chronic hepatitis B. Sci. Rep. 7, 10517 https:\/\/doi.org\/10.1038\/s41598-017-11278-x (2017).","DOI":"10.1038\/s41598-017-11278-x"},{"key":"39_CR17","doi-asserted-by":"publisher","unstructured":"Gorden, D. L. et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J. Lipid. Res. 56 722\u2013736 https:\/\/doi.org\/10.1194\/jlr.P056002 (2015).","DOI":"10.1194\/jlr.P056002"},{"key":"39_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.hbpd.2021.05.008","volume":"20","author":"ZH Wang","year":"2021","unstructured":"Wang, Z. H. et al. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver. Hepatobiliary Pancreat. Dis. Int. 20, 452\u2013459 https:\/\/doi.org\/10.1016\/j.hbpd.2021.05.008 (2021).","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"39_CR19","doi-asserted-by":"publisher","unstructured":"Mucinski, J. M. et al. Insulin sensitivity and skeletal muscle mitochondrial respiration in black and white women with obesity. J. Clin. Endocrinol. Metab. 110, e2026-e2036 https:\/\/doi.org\/10.1210\/clinem\/dgae600 (2024).","DOI":"10.1210\/clinem\/dgae600"},{"key":"39_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2337\/dc12-0544","volume":"36","author":"T Tillin","year":"2013","unstructured":"Tillin, T. et al. Insulin resistance and truncal obesity as important determinants of the greater incidence of diabetes in indian asians and African Caribbeans compared with Europeans. Diab. Care 36, 383\u2013393 https:\/\/doi.org\/10.2337\/dc12-0544 (2013).","journal-title":"Diab. Care"},{"key":"39_CR21","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1002\/hep.25712","volume":"56","author":"R Kumar","year":"2012","unstructured":"Kumar, R., Sharma, M. K. & Sarin, S. K. Does reference value of \u201cNormal Liver Stiffness\u201d using fibroscan have a regional variation? Hepatology 56, 1183\u20131184 https:\/\/doi.org\/10.1002\/hep.25712 (2012).","journal-title":"Hepatology"},{"key":"39_CR22","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas, T. et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 66, 1022\u20131030 https:\/\/doi.org\/10.1016\/j.jhep.2016.12.022 (2017).","journal-title":"J. Hepatol."},{"key":"39_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/MCG.0b013e3181dd1348","volume":"45","author":"R Juluri","year":"2011","unstructured":"Juluri, R. et al. Generalizability of the nonalcoholic steatohepatitis clinical research network histologic scoring system for nonalcoholic fatty liver disease. J. Clin. Gastroenterol. 45, 55\u201358 https:\/\/doi.org\/10.1097\/MCG.0b013e3181dd1348 (2011).","journal-title":"J. Clin. Gastroenterol."},{"key":"39_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30750-5","volume":"13","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Machine learning classifiers for screening nonalcoholic fatty liver disease in general adults. Sci. Rep. 13, 3638 https:\/\/doi.org\/10.1038\/s41598-023-30750-5 (2023).","journal-title":"Sci. Rep."},{"key":"39_CR25","doi-asserted-by":"publisher","unstructured":"Bhaskar, A. K. et al. A high throughput lipidomics method using scheduled multiple reaction monitoring. Biomolecules 12, 709 https:\/\/doi.org\/10.3390\/biom12050709 (2022).","DOI":"10.3390\/biom12050709"},{"key":"39_CR26","doi-asserted-by":"publisher","unstructured":"Khan, M. J. et al. Evaluating a targeted multiple reaction monitoring approach to global untargeted lipidomic analyses of human plasma. Rapid Commun. Mass Spectrom. 34, e8911 https:\/\/doi.org\/10.1002\/rcm.8911 (2020).","DOI":"10.1002\/rcm.8911"},{"key":"39_CR27","doi-asserted-by":"publisher","first-page":"D463","DOI":"10.1093\/nar\/gkv1042","volume":"44","author":"M Sud","year":"2016","unstructured":"Sud, M. et al. Metabolomics Workbench: an international repository for metabolomics data and metadata, metabolite standards, protocols, tutorials and training, and analysis tools. Nucleic Acids Res. 44, D463\u2013D470 https:\/\/doi.org\/10.1093\/nar\/gkv1042 (2016).","journal-title":"Nucleic Acids Res."},{"key":"39_CR28","doi-asserted-by":"publisher","first-page":"W398","DOI":"10.1093\/nar\/gkae253","volume":"52","author":"Z Pang","year":"2024","unstructured":"Pang, Z. et al. MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation. Nucleic Acids Res. 52, W398\u2013W406 https:\/\/doi.org\/10.1093\/nar\/gkae253 (2024).","journal-title":"Nucleic Acids Res."},{"key":"39_CR29","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/eurheartj\/ehad161","volume":"44","author":"NS Nurmohamed","year":"2023","unstructured":"Nurmohamed, N. S. et al. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction. Eur. Heart J. 44, 1594\u20131607 https:\/\/doi.org\/10.1093\/eurheartj\/ehad161 (2023).","journal-title":"Eur. Heart J."},{"key":"39_CR30","doi-asserted-by":"publisher","first-page":"436","DOI":"10.4254\/wjh.v12.i8.436","volume":"12","author":"S Kartsoli","year":"2020","unstructured":"Kartsoli, S., Kostara, C. E., Tsimihodimos, V., Bairaktari, E. T. & Christodoulou, D. K. Lipidomics in non-alcoholic fatty liver disease. World J. Hepatol. 12, 436\u2013450 https:\/\/doi.org\/10.4254\/wjh.v12.i8.436 (2020).","journal-title":"World J. Hepatol."},{"key":"39_CR31","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1007\/s00125-013-2981-2","volume":"56","author":"M Ore\u0161i\u010d","year":"2013","unstructured":"Ore\u0161i\u010d, M. et al. Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. Diabetologia 56, 2266\u20132274 https:\/\/doi.org\/10.1007\/s00125-013-2981-2 (2013).","journal-title":"Diabetologia"},{"key":"39_CR32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1021\/ac051495j","volume":"78","author":"S Bijlsma","year":"2006","unstructured":"Bijlsma, S. et al. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal. Chem. 78, 567\u2013574 https:\/\/doi.org\/10.1021\/ac051495j (2006).","journal-title":"Anal. Chem."},{"key":"39_CR33","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","volume":"128","author":"V Ratziu","year":"2005","unstructured":"Ratziu, V. et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128, 1898\u20131906 https:\/\/doi.org\/10.1053\/j.gastro.2005.03.084 (2005).","journal-title":"Gastroenterology"},{"key":"39_CR34","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.3390\/ijms22083899","volume":"22","author":"M Notarnicola","year":"2021","unstructured":"Notarnicola, M. et al. Nonalcoholic fatty liver disease: focus on new biomarkers and lifestyle interventions. Int. J. Mol. Sci. 22, 3899 https:\/\/doi.org\/10.3390\/ijms22083899 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"39_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.semcancer.2022.02.004","volume":"86","author":"SLW Tan","year":"2022","unstructured":"Tan, S. L. W., Israeli, E., Ericksen, R. E., Chow, P. K. H. & Han, W. The altered lipidome of hepatocellular carcinoma. Semin. Cancer Biol. 86, 445\u2013456 https:\/\/doi.org\/10.1016\/j.semcancer.2022.02.004 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"39_CR36","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/ijms22041816","volume":"22","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee, S., Balram, A. & Li, W. Convergence: lactosylceramide-centric signaling pathways induce inflammation, oxidative stress, and other phenotypic outcomes. Int. J. Mol. Sci. 22, 1816 https:\/\/doi.org\/10.3390\/ijms22041816 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"39_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.molmed.2018.10.009","volume":"25","author":"J Kurz","year":"2019","unstructured":"Kurz, J., Parnham, M. J., Geisslinger, G. & Schiffmann, S. Ceramides as novel disease biomarkers. Trends Mol. Med. 25, 20\u201332 https:\/\/doi.org\/10.1016\/j.molmed.2018.10.009 (2019).","journal-title":"Trends Mol. Med."},{"key":"39_CR38","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.3390\/ijms22116145","volume":"22","author":"S Groux-Degroote","year":"2021","unstructured":"Groux-Degroote, S. & Delannoy, P. Cancer-associated glycosphingolipids as tumor markers and targets for cancer immunotherapy. Int. J. Mol. Sci. 22, 6145 https:\/\/doi.org\/10.3390\/ijms22116145 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"39_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156063","volume":"162","author":"S Muralidharan","year":"2025","unstructured":"Muralidharan, S. et al. Serum lipidomic signatures in patients with varying histological severity of metabolic-dysfunction associated steatotic liver disease. Metabolism 162, 156063 https:\/\/doi.org\/10.1016\/j.metabol.2024.156063 (2025).","journal-title":"Metabolism"},{"key":"39_CR40","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/hep4.1188","volume":"2","author":"R Mayo","year":"2018","unstructured":"Mayo, R. et al. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: results from discovery and validation cohorts. Hepatol. Commun. 2, 807\u2013820 https:\/\/doi.org\/10.1002\/hep4.1188 (2018).","journal-title":"Hepatol. Commun."},{"key":"39_CR41","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.cmet.2020.03.010","volume":"31","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis. Cell Metab. 31, 969\u2013986.e7 https:\/\/doi.org\/10.1016\/j.cmet.2020.03.010 (2020).","journal-title":"Cell Metab."},{"key":"39_CR42","doi-asserted-by":"publisher","unstructured":"Calzada, E., Onguka, O. & Claypool, S. M. Phosphatidylethanolamine metabolism in health and disease. 321, 29\u201388 https:\/\/doi.org\/10.1016\/bs.ircmb.2015.10.001 (2016).","DOI":"10.1016\/bs.ircmb.2015.10.001"},{"key":"39_CR43","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.nut.2004.01.020","volume":"20","author":"A Misra","year":"2004","unstructured":"Misra, A. & Vikram, N. K. Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implications. Nutrition 20, 482\u2013491 https:\/\/doi.org\/10.1016\/j.nut.2004.01.020 (2004).","journal-title":"Nutrition"},{"key":"39_CR44","doi-asserted-by":"crossref","unstructured":"Wulan, S. N., Westerterp, K. R. & Plasqui, G. Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians. Maturitas. 65, 315\u2013319 (2010).","DOI":"10.1016\/j.maturitas.2009.12.012"},{"key":"39_CR45","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/s42255-024-01101-z","volume":"6","author":"J McLaren","year":"2024","unstructured":"McLaren, J. et al. Weight gain leads to greater adverse metabolic responses in South Asian compared with white European men: the GlasVEGAS study. Nat. Metab. 6, 1632\u20131645 https:\/\/doi.org\/10.1038\/s42255-024-01101-z (2024).","journal-title":"Nat. Metab."},{"key":"39_CR46","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1007\/s10620-024-08540-4","volume":"69","author":"CE Fu","year":"2024","unstructured":"Fu, C. E. et al. Sex and race-ethnic disparities in metabolic dysfunction-associated steatotic liver disease: an analysis of 40,166 individuals. Dig. Dis. Sci. 69, 3195\u20133205 https:\/\/doi.org\/10.1007\/s10620-024-08540-4 (2024).","journal-title":"Dig. Dis. Sci."},{"key":"39_CR47","doi-asserted-by":"publisher","first-page":"bvae63.048","DOI":"10.1210\/jendso\/bvae163.048","volume":"8","author":"M Shaheen","year":"2024","unstructured":"Shaheen, M., Schrode, K., Pan, D., Najjar, S. M. & Friedman, T. C. 12411 trends in metabolic dysfunction-associated steatotic liver disease (MASLD) by race\/ethnicity: data from NHANES 1988 to 2018. J. Endocr. Soc. 8, bvae63.048\u00a0https:\/\/doi.org\/10.1210\/jendso\/bvae163.048 (2024).","journal-title":"J. Endocr. Soc."},{"key":"39_CR48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3390\/metabo12020192","volume":"12","author":"TA Mazi","year":"2022","unstructured":"Mazi, T. A. et al. Plasma oxylipin profile discriminates ethnicities in subjects with non-alcoholic steatohepatitis: an exploratory analysis. Metabolites 12, 192 https:\/\/doi.org\/10.3390\/metabo12020192 (2022).","journal-title":"Metabolites"},{"key":"39_CR49","doi-asserted-by":"publisher","first-page":"e003385","DOI":"10.1136\/bmjdrc-2023-003385","volume":"11","author":"JYH Seah","year":"2023","unstructured":"Seah, J. Y. H., Sim, X., Khoo, C. M., Tai, E. S. & Dam, R. M. Differences in type 2 diabetes risk between East, South, and Southeast Asians living in Singapore: the multi-ethnic cohort. BMJ Open Diab. Res. Care 11, e003385 https:\/\/doi.org\/10.1136\/bmjdrc-2023-003385 (2023).","journal-title":"BMJ Open Diab. Res. Care"}],"container-title":["Communications Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44528-026-00039-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44528-026-00039-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44528-026-00039-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:02:40Z","timestamp":1792256560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44528-026-00039-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39"],"URL":"https:\/\/doi.org\/10.1038\/s44528-026-00039-w","relation":{},"ISSN":["3091-4841"],"issn-type":[{"value":"3091-4841","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"41"}}